Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch1 signaling impairs regulatory T cells during multisystem inflammatory syndrome in children
Magali Noval Rivas, Moshe Arditi
Magali Noval Rivas, Moshe Arditi
Published January 3, 2023
Citation Information: J Clin Invest. 2023;133(1):e166016. https://doi.org/10.1172/JCI166016.
View: Text | PDF
Commentary

Notch1 signaling impairs regulatory T cells during multisystem inflammatory syndrome in children

  • Text
  • PDF
Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a rare pediatric inflammatory disorder characterized by immune cell hyperactivation, cytokine storm, and the production of autoantibodies. The mechanisms underlying such immune dysregulation still need to be unraveled. In this issue of the JCI, Benamar et al. demonstrated the critical role of the Notch receptor 1/CD22 (Notch1/CD22) axis in Tregs, which, when activated, impairs Treg functions and promotes inflammation. They showed that the Notch1/CD22 axis contributed to dysregulated immune responses in MIS-C. These findings may have implications for MIS-C and many other inflammatory diseases.

Authors

Magali Noval Rivas, Moshe Arditi

×

Figure 1

Immune responses are dysregulated during MIS-C.

Options: View larger image (or click on image) Download as PowerPoint
Immune responses are dysregulated during MIS-C.
(A) MIS-C develops in ch...
(A) MIS-C develops in children two to five weeks after SARS-CoV-2 infection or exposure. Patients present with fever and elevated markers of inflammation associated with gastrointestinal (GI), cardiovascular, and neurological manifestations. (B) MIS-C is characterized by increased activation of neutrophils, monocytes, and NK cells. Decreased proportions of naive T cells (CD4+ Tconv and Tregs) and increased proportions of activated cells are also reported during MIS-C. Furthermore, TCR repertoire skewing and an expansion of TRBV11-2 T cell clonotypes, increased frequencies of plasmablasts, and the presence of autoantibodies have also been reported during MIS-C. In this issue of the JCI, Benamar et al. show that MIS-C was also associated with dysregulated Treg responses. In the presence of IL-1β and IL-6, Tregs from patients with MIS-C upregulated the expression of Notch1, CD22, and the gut-homing integrin α4β7. Activation of the Notch1/CD22 pathway in Tregs resulted in their instability, decreased Foxp3 expression, and subversion toward IFN-γ–producing effector cells, further propagating the MIS-C hyperinflammatory response. Blocking CD22 or using rapamycin, an mTORC1 inhibitor, inhibited the Notch1/CD22-triggered dysregulation of Tregs (18). CRP, C-reactive protein; LV, left ventricular; NT-proBNP, N-terminal pro-brain natriuretic peptide.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts